D. Craig Allred - Concepedia

Author

D. Craig Allred

Also Known As

Budd, G. Thomas, D C Allred, D Craig Allred, D. C. Allred, D. CRAIG ALLRED, D. Craig Allred, D. Craig. Allred, D.C. Allred, D.Craig Allred, Donald C. Allred

165

Publications

31.6K

Citations

H-Index

Concepts

All Affiliations

Baylor College of Medicine The University of Texas Health Science Center at San Antonio Washington University in St. Louis The University of Texas MD Anderson Cancer Center Methodist Hospital

About

D. Craig Allred is an author at Baylor College of Medicine specializing in medicine, breast cancer, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	51	7.4K
2	Cell Biology	25	27	3.5K
3	Health Sciences	3	3	573
4	Engineering	2	2	896
5	Biostatistics	1	1	116

D. Craig Allred

Publications

28.7K

Citations

H-Index

Page 1

	Year	Citations
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz, Journal of Clinical Oncology	2006	4.5K
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks, Journal of Clinical Oncology	2013	4K
Prognostic and predictive factors in breast cancer by immunohistochemical analysis. D. Craig Allred, Jennet Harvey, Melora D. Berardo, PubMed	1998	2.2K
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz, Archives of Pathology & Laboratory Medicine	2007	1.8K
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks, Archives of Pathology & Laboratory Medicine	2013	1.8K
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Kathy S. Albain, William E. Barlow, Steven Shak, The Lancet Oncology 21-Gene Recurrence ScoreBreast OncologyMedicineRandomised TrialPathology	2009	1.4K
Whole-genome analysis informs breast cancer response to aromatase inhibition Matthew J. Ellis, Li Ding, Dong Shen, Nature	2012	1K
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Jenny C. Chang, Eric C. Wooten, Anna Tsimelzon, The Lancet Breast OncologyEngineeringMedicineTherapeutic ResponseCancer Genomics	2003	885
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031 Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Journal of Clinical Oncology	2011	554
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer D. Craig Allred, Gary M. Clark, Rafael Molina, Human Pathology Breast OncologyMedicinePathologyBreast CancerOther Prognostic Factors	1992	409

Page 1